Supplemental material
Leukemia & Lymphoma
Volume 57, 2016 - Issue 9
Open access
2,868
Views
16
CrossRef citations to date
0
Altmetric
Letters to the Editor
Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
Robert M. RifkinUS Oncology Research, Inc., The Woodlands, TX, USA; Correspondence[email protected]
, Rafat AbonourIndiana University Cancer Center, Indianapolis, IN, USA;
, Jatin J. ShahDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
, Jayesh MehtaDivision of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;
, Mohit NarangMaryland Oncology Hematology, Columbia, MD, USA;
, Howard TerebeloProvidence Cancer Center Institute, Southfield, MI, USA;
, Cristina GasparettoDivision of Cellular Therapy, Duke University Medical Center, Durham, NC, USA;
, Kathleen ToomeySteeplechase Cancer Center, Somerville, NJ, USA;
, James W. HardinEpidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA;
, Jane Jie LuCelgene Corporation, Summit, NJ, USA;
, Laurie KenvinCelgene Corporation, Summit, NJ, USA;
, Shankar SrinivasanCelgene Corporation, Summit, NJ, USA;
, Robert KnightCelgene Corporation, Summit, NJ, USA;
, Yasir NagarwalaCelgene Corporation, Summit, NJ, USA;
& Brian G. M. DurieCedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
show all
Pages 2228-2231
|
Received 21 Sep 2015, Accepted 10 Dec 2015, Published online: 13 Jan 2016
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.